ARCUTIS BIOTHERAPEUTICS INCORPORATED (ARQT)

Arcutis Biotherapeutics stock has delivered a very strong 176.6% return over the past three years, yet the broader valuation checks currently suggest it does not stand out as obviously expensive or obviously cheap. With the shares last closing at US$27.99 and the stock screening as "about right" ...

Arcutis Biotherapeutics (ARQT) is back in focus as Wall Street looks ahead to its June 2026 quarter earnings report on August 5, with expectations centered on higher earnings and revenue. See our latest analysis for Arcutis Biotherapeutics. At a recent share price of $27.99, Arcutis Biotherapeutics …

Ares Capital meets Q2 earnings estimates, but rising expenses and unrealized losses weigh on results even as investment income improves.

Q2 revenue reached $500.7M with Adjusted EBITDA of $211.5M at a 42.2% margin. Net loss was $4.9M as IPO proceeds of $1.22B funded $946M of term debt repayment.

Arcutis Biotherapeutics, Inc. recently appointed Christopher “Chris” Peetz, co-founder and CEO of Mirum Pharmaceuticals, to its Board of Directors, bringing extensive biopharmaceutical, finance, and M&A experience to the company. His background in scaling rare-disease platforms, executing ...